Skip to main content
[Preprint]. 2023 Jun 12:rs.3.rs-3015916. [Version 1] doi: 10.21203/rs.3.rs-3015916/v1

Fig. 2.

Fig. 2

Toxicities associated with venetoclax and a hypomethylating agent in relapsed or refractory AML. A. Frequencies of high-grade hematological toxicity; significantly fewer patients had grade 3 or higher lymphocytopenia compared with the remaining hematological toxicities (p = 0.018). B. Causes of death in relapsed or refractory AML treated with venetoclax and a hypomethylating agent; death from underlying disease occurred significantly more frequently than any other cause (p < 0.0001)